Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

NCT02369874 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

736

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

Interventions

DRUG: MEDI4736
DRUG: MEDI4736 + Tremelimumab
DRUG: Standard of Care

Sponsor

AstraZeneca